News AZ boasts phase 3 win for self-administered gMG drug Alexion has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment for gMG.
News AstraZeneca sifts for efficacy crumbs in amyloidosis trial AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.
News Cheaper Soliris biosimilars reach the US market The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand.
News Storybook can help kids understand rare kidney disease An e-Book aimed at children with rare kidney disease aHUS can help them understand the condition, deal with emotions, and find support, says Alexion.
News FDA experts lukewarm on AZ's anticoagulant antidote Andexxa AstraZeneca is facing some pushback as it tries to upgrade anticoagulant antidote drug Andexxa to full approval in the US
News FDA clears Amgen’s Bkemv as first biosimilar of Soliris The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemi
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.